



Indexed in: PubMed



an Open Access Journal by MDPI

Emerging Therapeutic Approaches for Gastrointestinal Malignancies and the Tumour Microenvironment

Guest Editors:

Dr. Khurum Khan

Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London NW1 2BU, UK

Dr. Kai-Keen Shiu

Department of Gastrointestinal Oncology, University College London Hospital NHS Foundation Trust, London NW1 2PG, UK

Umair Mahmood

University College Hospital Macmillan Cancer Centre, Huntley Street, London WC1E 6AG. UK

Deadline for manuscript submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

In this Special Issue, a collection of studies on the current state of preclinical and clinical investigations shall be assembled. Studies that investigate new promising therapeutic targets, and innovative pathways as well as submissions that evaluate targeted therapies in combination with immuno-therapy and/or conventional systemic therapies, are encouraged. The aim is to summarize the interdisciplinary nature of gastrointestinal treatment, with a focus on targeted therapeutic strategies.

Potential topics include, but are not limited to, the following:

- Current and new therapeutic targets in gastrointestinal cancer subtypes;
- Diagnosis and selection of patients with gastrointestinal cancers for targeted therapy;
- Personalized medicine initiatives for gastrointestinal malignancies;
- Role of multi-modality treatment in the setting of neoadjuvant therapy;
- Implications of the combination of targeted therapeutics with immune-therapies and/or conventional chemotherapies.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us